esquire HCT ion trap mass spectrometer

Web link http://www.bdal.com/us/products/lc-ms/ion-trap.html

	Next higher product group	ion trap mass spectrometer LC/MS system
	Status	2003-03-10 sales start
	Price	USD 225,000 (price 2003-03-10)
	Document for price	Bruker Daltonics, Inc.. (3/10/03). "Press Release: Bruker Daltonics Introduces Esquire HCT with UltraScan, a Novel High Capacity Trap for Faster, Even More Sensitive Bioanalysis. New Esquire HCT is Ten Times More Sensitive and Features 26 kDa/sec UltraSc
	Organisation	Bruker Daltonics (Group)
	Today	Bruker Corporation (Group)
	Group	Bruker Corporation (Group)

Bruker Daltonics, Inc.. (3/10/03). "Press Release: Bruker Daltonics Introduces Esquire HCT with UltraScan, a Novel High Capacity Trap for Faster, Even More Sensitive Bioanalysis. New Esquire HCT is Ten Times More Sensitive and Features 26 kDa/sec UltraSc

At PittCon 2003, Bruker Daltonics Inc. (NASDAQ: BDAL) today introduces the esquire HCT(TM), a novel ultra-high performance ion trap mass spectrometer for dramatically faster and more sensitive analysis in proteomics and metabolomics. This next-generation high capacity trap (HCT) combines substantially higher ion storage capacity with a proprietary ultrahigh-performance scan mode for the ultimate in ion trap research performance.

Specifically, in addition to greatly increased storage capacity for ions, the esquire HCT features the breakthrough UltraScan(TM) mode for 26,000 Dalton/second analysis, while retaining better than unit mass resolution. The UltraScan is thus 5-6 times faster than other older-generation ion traps or recent triple-quadrupole derived so-called "linear" traps. The esquire HCT also offers a unique fast PeptideScan(TM) mode that can differentiate doubly and triple charged peptides in proteomic analysis over the entire mass range, again at scan speeds that dramatically exceed other types of ion traps.

The HCT high capacity trap together with the UltraScan bring full m/z-scan ion trap sensitivities for metabolites into the sub-picogram level for the first time, an order of magnitude sensitivity improvement compared to existing ion traps. The sensitivity for proteomics is expected to reach the low to mid attomole range for many proteins, an order of magnitude improvement.

The esquire HCT is unique due to its standard m/z-range up to 3,000 Dalton, a very desirable feature for proteomics, and a necessity for API-MALDI ion trap mass spectrometry. The extended mass range scan can even reach up to 6,000 Dalton.

The new ultra-high performance esquire HCT, priced at $225,000, extends Bruker Daltonics' esquire ion trap mass spectrometry product line, which already includes the existing high-end research-grade esquire3000plus, as well as the more routine esquire2000 bioanalytical LC/MS/MS system. The new esquire HCT can be fully integrated into the Proteineer(TM) proteomics suite, combining automated sample preparation systems, advanced mass spectrometry and bioinformatics.

Frank H. Laukien, Ph.D., President and CEO, commented: "The esquire HCT represents a breakthrough in ion trap capabilities. We expect that in most performance aspects that matter to mass spectrometrists who perform proteomics or small-molecule structural analysis, it will outperform, in many cases very significantly, existing technologies and products. We are confident that the esquire HCT will be well received by demanding research customers."

ABOUT BRUKER DALTONICS

Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information about Bruker Daltonics, please visit www.bdal.com or www.bdal.de

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein.

CONTACT:
Bruker Daltonics Inc.
Michael Willett,
978/663-3660, ext. 1411
Michael.Willett@bdal.com

Record changed: 2011-11-25

Follow Us!

Top News

Upcoming Events

Associations

Partners

esquire HCT ion trap mass spectrometer

Bruker Daltonics, Inc.. (3/10/03). "Press Release: Bruker Daltonics Introduces Esquire HCT with UltraScan, a Novel High Capacity Trap for Faster, Even More Sensitive Bioanalysis. New Esquire HCT is Ten Times More Sensitive and Features 26 kDa/sec UltraSc

More documents for ion trap mass spectrometer LC/MS system